RecruitingNCT07077213

18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients

Studying Tuberculosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Children's Hospital Medical Center, Cincinnati
Principal Investigator
Sanjay Jain, MD
Children's Hospital Medical Center, Cincinnati
Intervention
18F-FAPI-74(combination_product)
Enrollment
30 target
Eligibility
18 years · All sexes
Timeline
20262027

Study locations (1)

Collaborators

National Institutes of Health (NIH) · National Institute of Allergy and Infectious Diseases (NIAID) · SOFIE

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07077213 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis

← Back to all trials